Healthy Skepticism Library item: 11007
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Jack A.
Drug pricing: No cure, no cost.
BMJ 2007 Jul 21; 335:(7611):122-3
http://www.bmj.com/cgi/content/full/335/7611/122
Abstract:
The UK’s medicines watchdog caused a stir last month when it announced a groundbreaking payment by results plan with the drug company Janssen-Cilag. In draft proposals on which final guidance is due in October, Janssen-Cilag will charge the NHS for bortezomib (Velcade), its new drug for multiple myeloma, only if the patients show a complete or partial response.
It will rebate the full £25 000 (37 000; $50 000) cost of bortezomib for those who do not respond when treated in line with the drug’s indication-progressive multiple myeloma in patients who have received at least one previous drug and had, or are unsuitable for, bone marrow transplantation. This risk sharing approach is part of a broader effort by healthcare systems around the world to introduce value based pricing, in an attempt to clamp down on rising medicine costs.
Unveiling the proposal, Andrew Dillon, chief executive of the National Institute . . .
Market forces
Link between research and price
Keywords:
MeSH Terms:
Antineoplastic Agents/economics
Antineoplastic Agents/therapeutic use*
Behavioral Research/economics
Boronic Acids/economics
Boronic Acids/therapeutic use*
Drug Costs
Drug Industry/economics*
Great Britain
Humans
Interprofessional Relations
Marketing
Multiple Myeloma/drug therapy*
Multiple Myeloma/economics
Pyrazines/economics
Pyrazines/therapeutic use*
Remission Induction
State Medicine/economics
Treatment Failure
Substances:
Antineoplastic Agents
Boronic Acids
Pyrazines
bortezomib
